Paolo Milani, MD, PhD, Amyloidosis Research and Treatment Center, Pavia, Italy, comments on the impact of amyloid deposits in light chain (AL) amyloidosis, suggesting that light chains play a central role in disease toxicity. Dr Milani anticipates the results of clinical trials investigating whether the removal of amyloid during chemotherapy improves patient outcomes. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.